The patent application, submitted in January 2009 for approval, is for an invention related to the therapeutically effective amount of plant extracts that can be administered alone or in combination with a therapeutically effective amount of one or more anti-inflammatory agent and other pain removing agents and antifungal agent.
The invention is on methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy. Indena sells a Mucositis drug under the trade mark Samital.
The pre-grant opposition was filed by V K Gupta, CSIR, on December 2012 arguing that the use of various extracts for the treatment of various disease are known and claimed that the invention is not novel, not inventive and not patentable. He also submitted ancient Indian texts to substantiate his argument.
In its response, the company argued none of the exibits cited by the opponent disclose a composition containing all the active ingredients, as claimed in the instant invention for the treatment of mucositis.
One of the side effects of radiotherapy, and above all chemotherapy, is mucositis, which normally affects the astroenteric tracts especially the mouth, esophagus, stomach, intestine and vagina in women. It is a serious symptom and affects the quality life of the patient. None of the traditional knowledge speaks about mucositis, it said.
The opponent did not attend the hearing and not submitted any written note of arguments in respect to the pre-grant opposition. The Patent Officer observed that the opponent failed to establish all the grounds of opposition under anticipation, obviousness and non-patentability and rejected the pre-grant opposition.
After considering various revised claims and arguments the official observed that, in view of the prior art documents the person skilled in the art can easily arrive at the instantly claimed combination without involving any inventive skill. Also instant application fails to provide any improved synergistic effect for the claimed combination.
The Patent Office refused to proceed with the application as it observed that the patent cannot be allowed based on various sections in the Patents Act.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)